Although cancer drugs are considered to be quite expensive, two new pieces of analysis have concluded that you indeed get what you pay for. Well, at least when it comes to drugs made specifically for breast cancer patients.Both Aromasin and Herceptin have been proven in clinical trials to improve survival rates in breast cancer sufferers, according to this. In addition, newer breast cancer drugs just about to enter the pipeline (along with other cancer drugs) are raising questions from health officials and insurance companies, who are increasingly wanting to know how economically and clinically viable all these new products actually are.
Because, if newer cancer drugs are more expensive than traditional cancer treatments but are better for the medical and personal economies in the long run, then "you get what you pay for" will have been proven again.
